Drugs / AZD8154
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04480879 | Jul → Sep 2020 | asthma | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT03436316 | Jul 2018 → Jul 2019 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04187508 | Feb 2020 → Nov 2021 | asthma | AstraZeneca | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03436316 ↗ |
| Modality | Small molecule | — CHEMBL4558527 ↗ |
| Route | Inhaled | “single inhaled dose of AZD8154” NCT03436316 ↗ |